🇨🇭·1d agoIndustry
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Publisher
I
Idorsia
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on idorsia.com
Leave the platform to read the original full article on the publisher site.
Source: Idorsia
Scope: Industry
Related coverage
More related coverage
Canopy Growth·21h ago
CANOPY GROWTH’S APOLLO CANNABIS CLINICS NAMED BEST MEDICAL CANNABIS CLINIC
Voted best by Toronto Star Readers’ Choice Awards SMITH FALLS, ON, March 30, 2026 – Canopy Growth Co...
Zymeworks·23h ago
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Aimmune Therapeutics·1d ago
Nestlé introduces an innovative complete nutritional solution for children with special medical nutr…
Swedish Orphan Biovitrum·1d ago
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indicati...